This roundtable series assesses using Bruton kinase inhibitors in patients with chronic lymphocytic leukemia as first-line therapy, as discussed by key opinion leaders and participants at virtual live events.
Second Generation BTK Inhibitors Improve Survival in R/R CLL Setting
November 8th 2023In the second article of a 2-part series, William G. Wierda, MD, PhD, looks at the efficacy and safety outcomes with the second generation BTK inhibitor zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
ALPINE Trial Data Shows Effectiveness of Zanubrutinib in Relapsed CLL
January 15th 2024In the first article of a 2-part series, Sameer A. Parikh, MBBS, discusses the makeup and design of the phase 3 ALPINE study that showed the promise for the next-generation Bruton tyrosine kinase inhibitor zanubrutinib.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.